.AN2 Rehabs is reassessing its own service in feedback to lackluster midphase records, pledging to give up half its employees as well as cease a
Read moreALX’s waning CD47 response rate sends supply spiraling down
.ALX Oncology’s phase 2 stomach cancer response cost has weakened. After observing its CD47 blocker easily beat control over the first half of the trial,
Read moreAC Immune observes ‘landmark’ possible in Alzheimer’s drug data
.After greater than twenty years of service neurodegenerative health conditions, Swiss biotech air conditioning Invulnerable claims it could possess a game changer on its hands.The
Read more